Shineco

Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. It operates through the following segments: Luobuma Products, Herbal Products, and Other Agricultural Products. The Luobuma Products segment focuses in the development, manufacture, and distribution of specialized fabrics, textile products, and other by-products derived from an indigenous Chinese plant called Apocynum Venetum. The Herbal Products segment involves in the processing and distribution of traditional Chinese medicinal herbal products as well as other pharmaceutical products. The Other Agricultural Products segment comprises planting, processing, and distribution of green and organic agricultural produce and growing and cultivating of Chinese Yew trees. The company was founded on August 20, 1997 and is headquartered in Beijing, China.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. It operates through the following segments: Rapid Diagnostic and Other, Other Agricultural, and Healthy Meals Products. The Rapid Diagnostic and Other Products segment is conducted through Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases. The Other Agricultural Products segment is conducted through Wintus, which specializes in producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as trading of fresh fruit. The Healthy Meals Products segment is conducted through Fuzhou Meida, which specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. The company was founded on August 20, 1997 and is headquartered in Beijing, China.

Future FinTech Group

NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024.

Future FinTech Announces the Appointment of Hu Li as the New CEO

Beijing, July 15, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the closing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any.

Shineco Announces Closing of $2 Million Underwritten Public Offering

Shineco (NASDAQ: SISI ) stock is falling hard on Friday after the agricultural produce company announced the pricing of a public offering for its shares. This public offering has Shineco selling 1,869,160 shares of SISI stock for $1.07 each.

Why Is Shineco (SISI) Stock Down 54% Today?

Beijing, July 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the pricing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on July 15, 2024, subject to satisfaction of customary closing conditions.

Shineco Announces Pricing of $2 Million Underwritten Public Offering

Beijing, July 11, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced it has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase its shares of common stock. All of the shares of common stock and pre-funded warrants and the shares of common stock underlying the pre-funded warrants are being offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Shineco Announces Proposed Underwritten Public Offering

BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that on June 5, 2024, the Company received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a result of the closing bid price of the Company's common stock having been at least $1.00 per share for the period of 10 consecutive business days, from May 20, 2024 through June 4, 2024, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and advised that this matter is now closed.

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain non-U.S. investors (each individually, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the “Shares”) to the Purchasers in a private placement financing transaction (the “Offering”) at an offering price of $5.00 per share. The gross proceeds of the Offering are expected to be approximately $7,000,000, before the deduction of customary expenses. The Purchasers are a former related party of the Company, who agreed to purchase 1,000,000 shares of common stock, a management member of the Company, who agreed to purchase 200,000 shares of common stock, and an individual investor who agreed to purchase 200,000 shares of common stock. The Offering is expected to close, and the Shares are expected to be issued, on or about July 31, 2024.

Shineco, Inc. Announces Entering into a Securities Purchase Agreement with Gross Proceeds of $7.0 Million

BEIJING, June 20, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDA: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 18, 2024, it entered into an Investment Letter of Intent (the “Investment LOI”) with Beijing Oriental Meitong Technology Co., Ltd. (“Meitong Technology”) whereby Shineco intends to invest $20 million in Meitong Technology in exchange for 80% of Meitong Technology's shares. The Company believes that the acquisition of equity in Meitong Technology will add to the Company's core competencies and result in operating synergies that will enhance the Company's value proposition.

Shineco Enters into a Letter of Intent with Meitong Technology to Address China's Aging Population

Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 14, 2024, its 51% owned subsidiary, Shangkang Life Science and Technology (Jiangsu) Co., Ltd. (“Shangkang Life Science”) entered into a Strategic Cooperation Framework Agreement (“the Agreement”) with Turing Video (Shenzhen) Co., Ltd (“Turing Video”) to jointly develop a series of smart medical products and introduce their biotechnology and other innovative health solutions to the healthcare market.

Shineco Enters into an Agreement with Turing Video to Jointly Develop Intelligent Health Care Products

BEIJING , May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd.

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

BEIJING, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that the Company's Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-10. The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

Shineco Announces 1-for-10 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles.

Shineco Announces the Appointment of Two New Executive Officers

SISI Anticipates the Roll-Out of Additional Restaurants to Develop a Chain of Healthy Food Restaurants BEIJING, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today the grand opening of its first carry-out restaurant which will sell Shineco's new healthy and nutritious food brand, ‘Meida Nutritionary Restaurant”. Shineco's first carry-out restaurant is located on Baihuazhou Road, Cangshan, Fuzhou City, China.

Shineco Opens Healthy Food Restaurant with Focus on Advanced Nutrition

The Recent Acquisition of a Majority Stake in a Manufacturer of Antibacterial and Antiviral Fabrics Expected to Create Synergies for New Products

Shineco to Increase R&D to Explore New High-Tech Medical Product Applications

Shineco (NASDAQ: SISI ) stock is on the rise Tuesday without any clear news from the company this morning. Instead, it looks like traders can point to increased activity as the reason for today's rally.

Why Is Shineco (SISI) Stock Up 40% Today?

Registration with the NMPA, China's Regulatory Equivalent to the FDA, is a Prerequisite to Marketing and Distribution

Shineco Subsidiary Receives Marketing Approval from China's Regulatory Body for its Cardiac 5-Minute Test

BEIJING, June 28, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that on June 15, 2023, its wholly owned subsidiary, Shineco Life Science Research Co., Ltd. (“Shineco Life Science”), signed a joint venture cooperation agreement (the “Agreement”) with Yangzhou Kangling Medical Co., Ltd. ("Kangling Medical"), to establish a joint venture company, Shangkang Life Science and Technology (Jiangsu) Co., Ltd (“Shangkang Life Science”). The joint venture will be formed to improve the delivery of healthcare services and medical products throughout China.

Shineco Enters into Cooperation Agreement with Kangling Medical to Develop New Medical Products Company

Association with the Chamber Will Improve Visibility and Could Lead to Potential Collaborations BEIJING, June 08, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that in May 2023, its wholly owned subsidiary. Shineco Life Science Research Co., Ltd.

Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce

BEIJING, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company's controlled affiliate Changzhou Biowin Pharmaceutical Co., Ltd. ("CBP") has received the Prior Approval Supplement from the Jiangsu Medical Products Administration (“NMPA Jiangsu Bureau”) for the marketing approval of “Cardiac 5-minute Test.” This product is a combo test of three major cardiac markers and can detect cardiac troponin I (“cTnI”), myoglobin and fatty acid binding protein (“FABP”) for the clinical diagnosis of acute myocardial infarction (“AMI”) in one test. We believe it is a breakthrough of the clinical diagnosis of AMI and takes only 5 minutes to complete detection.

Shineco, Inc. Subsidiary Receives Prior Approval Supplement from the NMPA Jiangsu Bureau for the Marketing Approval of “Cardiac 5-Minute Test”

BEIJING, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc.(“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that its controlling affiliate, Changzhou Biowin Pharmaceutical Co., Ltd. (“CBP”), has been granted a patent (US 11,458,476 B2) by the United States Patent and Trademark Office (“USPTO”) protecting its in-situ fecal specimen sampling device for the use of stool test sample collection, and the marketing approval of the product by the Food and Drug Administration (“FDA”). This product provides a massager-like fingertip swab, a collection tube and a lid with unidirectional sampling inlet. It is a leading stool sample collection device on the market that can be used for self-collection while defecation and does not need a container or plastic bag for this process. After collection, the laboratory staff can finish all of the testing procedures without opening the sample tube.

Shineco, Inc Subsidiary, Granted USPTO Patent and FDA Marketing Approval for Its In-situ Fecal Specimen Sampling Device

BEIJING, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company's controlling affiliate Changzhou Biowin Pharmaceutical Co., Ltd. ("CBP"), a Chinese biotechnology company focusing on in-vitro diagnostic product research and development (“R&D”) and high-tech biomedical products manufacturing, attended MEDICA 2022 in Düsseldorf, Germany from November 14 to 17, 2022. MEDICA 2022 is one of the world's largest medical trade fair held annually for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. With an exhibition area of more than 108,000 square meters, the trade fair attracts visitors and exhibitors from approximately 70 countries worldwide.

Shineco, Inc. Attends MEDICA 2022 Düsseldorf Germany

BEIJING, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc.(“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that on October 21, 2022, the Company, through its wholly-owned subsidiary, Shineco Life Science Research Co., Ltd. ("Shineco Life Science"), entered into a Stock Purchase Agreement (the "Agreement") to acquire 51% of the issued equity interest of Changzhou Biowin Pharmaceutical Co., Ltd. ("CBP"), a Chinese biotechnology company focusing on in-vitro diagnostic product research and development (“R&D”) and high-tech biomedical products manufacturing. The total amount of this transaction exceeds US$10 million, to be paid in cash and the Company's common stock. This acquisition is a critical initiative of the Company's business strategy of stepping into the Point-of-Care Testing (“POCT”) industry.

Shineco, Inc. to Acquire Controlling Equity Interest in Changzhou Biowin Pharmaceutical Co., Ltd to Step into Point-of-Care Testing Industry

BEIJING, April 14, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that it has entered into a securities purchase agreement (the “Agreement”) on April 11, 2022 for the sale of aggregate gross proceeds of approximately US$2.2 million of its registered common stock at a price of $2.26 per share with an accredited investor. The closing of the transaction is expected to occur on or about April 15, 2022, subject to the satisfaction of customary closing conditions for this transaction.

Shineco, Inc. Announces Entering into a Securities Purchase Agreement with Gross Proceeds of US$2.2 Million

BEIJING, March 28, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, today announced the board of directors (the “Board”) and officer changes effective on March 25, 2022. Effective on March 25, 2022, for personal reasons, Mr. Yuying Zhang resigned from his position as Chairman and a member of the Board. The Company's Board has appointed current Board member Mr. Mike Zhao as the Chairman of the Board, replacing Mr. Zhang. Additionally, the Board appointed Mr. Xiqiao Liu to the Board to fill the vacancy created by Mr. Zhang's resignation. Mr. Liu has also been appointed to serve as the Company's Chief Operating Officer.

Shineco, Inc. Announces Board and Officer Changes

BEIJING, March 18, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced the Company has signed a fund establishment cooperation agreement (the “Agreement”) with Beijing Jin Tai Yuan Feng Investment Management Co., Ltd. (“JTYF”) on March 16, 2022, planning to introduce a life science-focused limited partnership fund (the “Fund”) in Shandong Province, China. JTYF currently plans to raise RMB200 million for the Fund.

News for Shineco Stock (SISI)